KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt RepaymentsR&D In ProcessShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) EBIAT (2016 - 2025)

Historic EBIAT for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $3.6 billion.

  • Pfizer's EBIAT fell 2077.66% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 billion, marking a year-over-year increase of 8053.65%. This contributed to the annual value of $8.1 billion for FY2024, which is 27117.86% up from last year.
  • Latest data reveals that Pfizer reported EBIAT of $3.6 billion as of Q3 2025, which was down 2077.66% from $2.9 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's EBIAT registered a high of $9.9 billion during Q3 2022, and its lowest value of -$2.4 billion during Q4 2023.
  • Over the past 5 years, Pfizer's median EBIAT value was $3.1 billion (recorded in 2024), while the average stood at $3.4 billion.
  • Its EBIAT has fluctuated over the past 5 years, first tumbled by 12762.29% in 2023, then surged by 600000.0% in 2025.
  • Over the past 5 years, Pfizer's EBIAT (Quarter) stood at $590.0 million in 2021, then crashed by 61.86% to $225.0 million in 2022, then tumbled by 73.33% to $60.0 million in 2023, then skyrocketed by 7368.33% to $4.5 billion in 2024, then fell by 20.78% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q3 2025, $2.9 billion for Q2 2025, and $3.0 billion during Q1 2025.